Press release
Glaucoma - Pipeline Insight, 2025: Advancing Beyond IOP Control Toward Neuroprotection and Vision Preservation | DelveInsight
Glaucoma, a leading cause of irreversible blindness worldwide, is traditionally managed through therapies that lower intraocular pressure (IOP). However, as understanding of the disease evolves, there is growing recognition of the need for neuroprotective strategies that address underlying optic nerve damage and retinal ganglion cell (RGC) loss.DelveInsight's "Glaucoma - Pipeline Insight, 2025" analyzes over 50+ emerging therapies that go beyond conventional IOP-lowering agents. The pipeline includes novel mechanisms such as ROCK inhibitors, nitric oxide-donating agents, neuroprotective peptides, complement pathway inhibitors, and gene therapies aimed at preserving vision and halting disease progression.
Key companies driving innovation include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, and TearClear, with many candidates in late-stage development or in combination regimens to enhance efficacy. Several therapies target underserved segments, such as normal-tension glaucoma or treatment-resistant patients.
The report offers detailed insights into trial designs, delivery systems (e.g., sustained-release implants, nanocarriers), and biomarkers for early diagnosis and response monitoring. As glaucoma care shifts toward holistic disease management, emerging therapies are aiming not just to reduce IOP but to preserve long-term visual function and quality of life.
This evolving landscape reflects a shift toward comprehensive, disease-modifying approaches that could transform glaucoma care in the coming years
Interested in learning more about the current treatment landscape and the key drivers shaping the Glaucoma pipeline? Click here: https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Glaucoma Pipeline Report
• DelveInsight's glaucoma pipeline analysis depicts a strong space with 50+ active players working to develop 50+ pipeline drugs for glaucoma treatment.
• The leading glaucoma companies include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others are evaluating their lead assets to improve the glaucoma treatment landscape.
• Key glaucoma pipeline therapies in various stages of development include DE-130A, PDP-716, NCX 470, DE-126, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, BTQ-1902, Nyxol, IN-A010, VVN539, and others.
• In May 2025, OcuSciences received FDA clearance for its OcuMet Beacon, a proprietary non-invasive device for assessing retinal health.
• In April 2025, BVI Medical received FDA 510(k) clearance for its Leos system, a minimally invasive glaucoma device offering Laser ECP with endoscopic visualization. Leos reduces IOP by targeting aqueous humor production and is backed by emerging clinical trial data.
• In December 2024, Gland Pharma received USFDA approval for its Latanoprost Ophthalmic Solution 0.005% (2.5 mL), a generic equivalent to Xalatan, for treating elevated intraocular pressure in open-angle glaucoma and ocular hypertension.
Request a sample and discover the recent breakthroughs happening in the glaucoma pipeline landscape at https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Glaucoma Overview
Glaucoma is a chronic, progressive eye disease that damages the optic nerve and is one of the leading causes of irreversible blindness worldwide. It is most commonly associated with elevated intraocular pressure (IOP), which results from impaired drainage of aqueous humor from the eye. However, glaucoma can also develop in individuals with normal IOP, highlighting the complexity of its underlying pathophysiology. The disease is typically asymptomatic in its early stages, earning it the nickname "the silent thief of sight," as significant vision loss can occur before a patient becomes aware of any issues.
There are several types of glaucoma, with the most common being primary open-angle glaucoma (POAG) and angle-closure glaucoma. Other less common types include normal-tension glaucoma, congenital glaucoma, and secondary glaucomas resulting from other medical conditions or trauma. Risk factors include age, family history, race (especially African or Asian descent), diabetes, and long-term corticosteroid use.
Current treatment strategies primarily aim to reduce IOP through medications (such as prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors), laser therapy, or surgery. However, these interventions do not address the underlying neurodegeneration, and many patients continue to experience progressive vision loss despite controlled IOP. As a result, there is a growing focus on developing neuroprotective and regenerative therapies to prevent optic nerve damage and preserve vision.
Find out more about glaucoma medication at https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Glaucoma Treatment Analysis: Drug Profile
NCX 470: Nicox Ophthalmics GmbH
NCX 470 is a next-generation nitric oxide (NO)-donating prostaglandin analog being developed by Nicox Ophthalmics. It combines the intraocular pressure (IOP)-lowering effects of prostaglandin F2α activity with the additional benefits of nitric oxide, which may improve ocular perfusion. This dual mechanism could make NCX 470 one of the most effective single-agent treatments for lowering IOP in patients with open-angle glaucoma or ocular hypertension. The drug is currently in Phase III clinical development.
DE-126 (ONO-9054): Santen Pharmaceuticals
DE-126 is a novel, once-daily prostaglandin analog eye drop designed to reduce IOP through a dual mechanism-activation of both FP and EP3 prostaglandin receptors. Since both receptors play a role in IOP reduction, DE-126 is expected to deliver superior efficacy compared to conventional FP receptor agonists. It is currently in Phase III clinical trials for open-angle glaucoma and ocular hypertension.
POLAT-001: Peregrine Ophthalmic
POLAT-001 is an extended-release formulation of latanoprost, delivered through nanoliposomes approximately 100 nm in size. This innovative liposomal platform, known as Lipolat, represents a significant advancement in ophthalmic nanomedicine, offering sustained drug delivery for glaucoma treatment. POLAT-001 has completed a pilot Phase IIa trial in the U.S. for the treatment of glaucoma.
Learn more about the novel and emerging glaucoma pipeline therapies at https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Glaucoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide
Scope of the Glaucoma Pipeline Report
• Coverage: Global
• Key Glaucoma Companies: Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
• Key Glaucoma Pipeline Therapies: DE-130A, PDP-716, NCX 470, DE-126, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, BTQ-1902, Nyxol, IN-A010, VVN539, and others.
To dive deep into rich insights for drugs used for glaucoma treatment, visit: https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Glaucoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Glaucoma Pipeline Therapeutics
6. Glaucoma Pipeline: Late-Stage Products (Phase III)
7. Glaucoma Pipeline: Mid-Stage Products (Phase II)
8. Glaucoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glaucoma - Pipeline Insight, 2025: Advancing Beyond IOP Control Toward Neuroprotection and Vision Preservation | DelveInsight here
News-ID: 4093011 • Views: …
More Releases from DelveInsight

Gene Therapy Market to Grow at a CAGR of 19.25% Through 2032, Driven by Breakthr …
The global gene therapy market is on a strong upward trajectory, fueled by scientific advancements, growing approvals, and rising demand for personalized and curative treatments. With a projected CAGR of 19.25% through 2032, gene therapy is transforming the treatment paradigm for genetic disorders, rare diseases, cancers, and even select infectious and neurodegenerative conditions.
Gene therapies offer the potential for long-term or permanent cures by delivering, altering, or replacing faulty genes at…

Global Spinal Implants Market to Grow at a CAGR of 5.50% Through 2032, Fueled by …
The spinal implants market is steadily expanding, driven by the increasing prevalence of degenerative spinal conditions, spinal injuries, deformities, and age-related disorders such as osteoporosis. With rising demand for motion-preserving and minimally invasive solutions, the market is undergoing a significant transformation shaped by advanced material science and surgical techniques.
Spinal implants play a pivotal role in stabilizing the spine, correcting deformities, and promoting spinal fusion after trauma or disease. The market…

Myelofibrosis - Pipeline Insight, 2025: Novel Disease-Modifying Therapies Target …
Myelofibrosis, a rare and chronic myeloproliferative neoplasm, is characterized by bone marrow fibrosis, abnormal blood cell production, and splenomegaly. Historically treated with symptom-focused therapies, the treatment landscape for myelofibrosis is now undergoing a significant transformation as disease-modifying approaches gain traction.
DelveInsight's "Myelofibrosis - Pipeline Insight, 2025" highlights over 40+ active pipeline candidates targeting various pathogenic mechanisms, including JAK-STAT signaling, fibrosis pathways, anemia management, and the malignant stem cell clone. Prominent therapeutic…

Thalassemia - Pipeline Insight, 2025: Advancing Curative and Disease-Modifying T …
Thalassemia, a group of inherited blood disorders characterized by defective hemoglobin synthesis, continues to pose significant clinical challenges despite existing transfusion and iron chelation therapies. As the focus shifts from symptomatic management to curative and disease-modifying strategies, the thalassemia treatment pipeline is undergoing a major transformation.
DelveInsight's "Thalassemia - Pipeline Insight, 2025" highlights over 28+ emerging therapies in development, ranging from gene therapies and gene editing approaches to novel erythroid maturation…
More Releases for Glaucoma
Micro-Invasive Glaucoma Implants Micro-Invasive Glaucoma Implants
Global Micro-Invasive Glaucoma Implants Market Definition: Micro-invasive glaucoma implants is performed for the treatment of the open- angle glaucoma and is done through an ab- interno approach. It is very safe and provides faster recovery as compared to the traditional methods. They usually lower the intraocular by increasing the flow or reducing the production of the aqueous humor. Increasing cases of the glaucoma worldwide is the major factor fueling the…
Glaucoma – Epidemiology Insights (2016-2028)
Glaucoma can be described as a group of diseases characterized by cupping of the optic nerve head and visual-field damage. These diseases differ from each other in terms of their causes, risk factors, demographics, symptoms, duration, treatment, and prognosis.
Download the sample report @ https://www.pharmaproff.com/request-sample/1159
The common identifiable features for all forms of glaucoma are loss of retinal ganglion cells, thinning of the retinal nerve fiber layer, and cupping of the…
Market Spotlight: Glaucoma
Boston, MA
ReportsWorldwide has announced the addition of a new report title Market Spotlight: Glaucoma to its growing collection of premium market research reports.
Glaucoma is not just one eye disease, but a group of eye conditions resulting in optic nerve damage, which may cause loss of vision and blindness. In glaucoma, damage to the optic nerve is usually caused by elevated intraocular pressure (IOP). IOP rises when passages that allow fluid…
North America Glaucoma Therapeutics Market grows with growing awareness regardin …
Glaucoma Therapeutics Market: Scope and Methodology
The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study…
Glaucoma Treatment Market : Rising Geriatric Population And Healthcare Expenditu …
Glaucoma is a chronic, degenerative, permanent disorder whose rate increases essentially with age rather than causing immediate blindness. According to a survey of WHO, Glaucoma is the second most common cause of blindness affecting the population worldwide after cataract (47.9%). In general, Glaucoma occurs as after effects of increased intraocular pressure (IOP) brought about by an abnormality or malfunctioning of the eye drainage system. The normal IOP is in…
Glaucoma Surgery Devices Market 2016: Glaucoma Systems, Glaucoma Laser Devices
Latest industry research report on Glaucoma surgery devices are used in the glaucoma treating procedure. These procedures include both surgical and laser therapies performed on a patient. The cases of blindness due to glaucoma is on rise across the several countries. Furthermore, the demand for both technologically as well as advanced surgical equipment has resulted in the popularity of glaucoma surgery devices industry, worldwide.
Sudden increase in the aging population and…